NeuroThera Labs Inc. Achieves Milestone in Quantum-Enabled Clinical Data Analytics Platform

Toronto, Ontario — July 31, 2026 — Leads & Copy — NeuroThera Labs Inc. (TSXV: NTLX), a clinical-stage biotech company, announced a significant technological advancement for its quantum platform designed for clinical data analytics. The platform has successfully processed real-world clinical data, generating biologically relevant analytical insights through an integrated quantum-enabled workflow.

The demonstrated workflow represents a complete end-to-end hybrid quantum-classical process, encompassing secure data ingestion and preparation, quantum-enabled analytical processing, and the generation of clinically interpretable insights. This process was executed within a quantum simulation environment engineered to emulate the quantum computational processes crucial to the Platform's analytical architecture.

NeuroThera's proprietary analytical framework is specifically designed to facilitate quantum-enhanced sampling for continuous probability distributions, a capability essential for advanced statistical analyses of clinical trial and biomedical datasets. The successful completion of this end-to-end analysis confirms the Platform's capacity to manage clinical-grade datasets throughout the entire analytical lifecycle, from secure ingestion and preparation to quantum-based processing and domain-relevant interpretation, all within a unified computational framework.

This milestone validates the Platform's ability to support a comprehensive hybrid quantum-classical analytical workflow. This workflow is intended to tackle complex, high-dimensional biomedical datasets by applying quantum-inspired and quantum-enabled methodologies to identify subtle patterns, while ensuring alignment with downstream scientific interpretation requirements.

Moving forward, NeuroThera's development roadmap for the Platform includes scaling up the size of supported datasets, further refining its quantum algorithms, and conducting performance studies. These studies aim to assess the potential contributions of quantum computing technologies to clinical research, clinical trial analytics, and precision medicine.

The Platform is being developed under CliniQuantum, a quantum-focused initiative that creates proprietary computational solutions for complex clinical data analytics. NeuroThera holds a 54.01% stake in CliniQuantum.

NeuroThera Labs Inc. is a clinical-stage pharmaceutical company dedicated to developing novel therapeutics for central nervous system disorders and other underserved health conditions through collaborations and innovative combinations.

Source: NeuroThera Labs Inc.